The historical rank and industry rank for Zhejiang Shengda Bio-Pharm Co's Net Margin % or its related term are showing as below:
SHSE:603079'
s Net Margin % Range Over the Past 10 Years
Min: -7.43 Med: 9.05 Max: 22.76
Current: 6.46
SHSE:603079's Net Margin % is ranked better than 53.29% of 957
companies
in the Drug Manufacturers industry
Industry Median: 5.58
vs SHSE:603079: 6.46
Zhejiang Shengda Bio-Pharm Co (SHSE:603079) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Zhejiang Shengda Bio-Pharm Co Net Margin % Related Terms
Zhejiang Shengda Bio-Pharm Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Shengda Bio-Pharm Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Shengda Bio-Pharm Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Shengda Bio-Pharm Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Zhejiang Shengda Bio-Pharm Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Shengda Bio-Pharm Co (SHSE:603079) has a Net Margin % of 6.96% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Zhejiang Shengda Bio-Pharm Co and its competitors. This is 23% below median its historical median of 9.05. According to the industry distribution chart, Zhejiang Shengda Bio-Pharm Co ranks #447 out of 957 companies in the Drug Manufacturers industry, placing it in the top 46.7%.
Is Zhejiang Shengda Bio-Pharm Co's Net Margin % too high?
Zhejiang Shengda Bio-Pharm Co's current Net Margin % of 6.96% is 23% below median its 10-year median of 9.05. The Drug Manufacturers industry median Net Margin % is 5.58. Zhejiang Shengda Bio-Pharm Co's value of 6.96% is 24.7% above this industry median. Based on the distribution chart, Zhejiang Shengda Bio-Pharm Co ranks #447 out of 957 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zhejiang Shengda Bio-Pharm Co has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Shengda Bio-Pharm Co's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zhejiang Shengda Bio-Pharm Co ranks #447 out of 957 companies for Net Margin %. This puts Zhejiang Shengda Bio-Pharm Co in the upper half of its industry. The industry median Net Margin % is 5.58. Zhejiang Shengda Bio-Pharm Co's value of 6.96% is 24.7% above this benchmark. While the company's 10-year median is 9.05 vs. the industry median of 5.58, Zhejiang Shengda Bio-Pharm Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.58, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Shengda Bio-Pharm Co's current Net Margin % of 6.96% is 24.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Zhejiang Shengda Bio-Pharm Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Shengda Bio-Pharm Co's current Net Margin % is 6.96%, which is 23% below median its own 10-year median of 9.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Shengda Bio-Pharm Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Shengda Bio-Pharm Co (SHSE:603079) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.37, compared to a current price of ¥11.18 — trading 22.2% below its estimated fair value. The current Net Margin % is 6.96%, which is 23% below median its 10-year median of 9.05 and 24.7% above the Drug Manufacturers industry median of 5.58. Zhejiang Shengda Bio-Pharm Co's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Zhejiang Shengda Bio-Pharm Co (SHSE:603079), the current Net Margin % is 6.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Shengda Bio-Pharm Co (SHSE:603079) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Shengda Bio-Pharm Co stock appears to be undervalued.
The current stock price of ¥11.18 is trading 22.2% below its estimated GF Value™ of ¥14.37.
GuruFocus considers Zhejiang Shengda Bio-Pharm Co to be Modestly Undervalued.
Key valuation signals for SHSE:603079:
Net Margin %: 6.96% (23% below median its 10-year median of 9.05)
GF Value™: ¥14.37 vs. price of ¥11.18 (22.2% below fair value)
Industry Position: 24.7% above the Drug Manufacturers median (#447 of 957)
No single metric tells the full story. See the SHSE:603079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Shengda Bio-Pharm Co Business Description
Zhejiang Shengda Bio-Pharm Co Ltd is a pharmaceutical company. It is mainly engaged in the research and development, and production of biotin and biological preservatives. Its product portfolio includes biotin, folic acid, and other vitamin products, nisin, natamycin, and sucrose fermentation products.
61GF Score
Get the complete analysis for SHSE:603079
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603079 has been successfully added to your 
